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Objective To detect the incidence of drug-resistant Plasmodium falciparum malaria
infection in immigrants and travellers in non-endemic Kuwait.
Methods Over a period of 3 years, July 1995 to September 1998, 1352 malaria patients
were enrolled in the study. Of these, 1293 were immigrants from countries where malaria
is endemic and 59 were non-immune travellers with a recent history of travel to these
countries. The in vitro drug sensitivity was determined in 892 patients.
Results In all, 892 of 1352 (66.0%) P. falciparum isolates were successfully cultured in
vitro for drug sensitivity and 419 (47.0%) isolates showed in vitro resistance to chlor-
oquine or mefloquine. Fifty-six (13.4%) isolates were resistant to both drugs. Chloroquine
resistance was observed in >70% of the isolates from Africa and India followed by
Pakistan (39.9%) and Bangladesh (35.9%). The resistance to mefloquine ranged from
26.2% in isolates from Sri Lanka to 47.5% in isolates from African countries.
Conclusion The study highlights the important trend in drug resistance in P. falciparum
malaria in immigrants from south-east Asian and African countries.
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I N T R O D U C T I O N
The spread of drug-resistant strains of malaria
parasites has made the prophylaxis and treatment
of the disease increasingly difficult, particularly
with chloroquine [1–3]. Drug resistance has been
implicated in the spread of malaria to new areas
and the re-emergence of malaria in areas in
which the disease had been eradicated. Drug resis-
tance has also played a significant role in the
occurrence and severity of malaria epidemics in
some areas. Part of this spread of drug resistance
may be attributed to mismanagement of malaria
control programs, poor infrastructure facilities
and rapid movement of refugees or populations
seeking work as well as to environmental changes
[3,4].
Indigenous malaria cases have not yet been
detected in Kuwait, but each year more than 800
cases of imported malaria infections are recorded
in Kuwait. More than 95% of these cases were
seen among the immigrant population residing
in Kuwait. Each year >500 000 individuals enter
Kuwait to work or to reside. The majority of
the expatriate population (>65%) comes from
areas in south-east Asia where malaria is endemic.
In addition, malaria cases were also seen in the
non-immune local population among those
who travelled to tropical areas for holidays or
business. Recently, drug-resistant Plasmodium
falciparum isolates have been reported in the nat-
ive population of the neighboring Gulf States of
Oman, Saudia Arabia and the United Arab
Emirates [5–9].
The information on the distribution and pat-
tern of drug-resistant P. falciparum parasites from
all tropical and subtropical areas is either not
available or has not been updated. The main
purpose of this study was to detect drug sensitivity
patterns to chloroquine and mefloquine in P.
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falciparum isolated from various migrant groups
residing in Kuwait and from non-immune Kuwaiti
or European residents.
M A T E R I A L S A N D M E T H O D S
Study group
From July 1995 until October 1998, 1352 patients
with suspected malaria were enrolled for the
study. These patients were selected randomly
from various immigrant groups with fever, com-
ing to Kuwait from their home countries where
malaria is endemic. The majority of these indivi-
duals came from India, Pakistan, Sri Lanka,
Bangladesh and Nigeria. This work was done
at the Malaria Laboratory, Medical Centre for
Labour Examination, Infectious Diseases Hospital
and Mubarak Al-Kabeer Teaching Hospital,
Faculty of Medicine, Kuwait University. The para-
sitemia in thick films was estimated by counting
parasites corresponding to 800 leucocytes. From
this figure, the parasite density was calculated
from the known white blood cell count. All slide-
positive mild malaria cases were treated with the
standard chloroquine phosphate dose of 25 mg/kg
over 3 days. All malaria patients were followed up
clinically, their blood was examined microscopi-
cally for malaria parasites on days 3, 7 and 14 after
treatment and whenever symptoms or fever were
reported. The study was reviewed and approved
by the ethical committee of the Research Division
of the Faculty of Medicine, Kuwait University.
In vitro assay
The micro in vitro drug sensitivity testing for
chloroquine and mefloquine was performed with
samples that were directly taken from the patient
prior to treatment. The drug sensitivity was deter-
mined in predosed plates from the World Health
Organization (WHO) following their standard
procedures [10]. Briefly, 200 mL of whole blood
was collected from the patient by finger prick
and added to 1.8 mL of RPMI-1640 culture med-
ium. Then, 50 mL of the diluted blood was added
to each well coated with various concentrations
of chloroquine and mefloquine. The plates were
incubated at 37 8C in 5% CO2 for 30 h. Thick films
were prepared from each well and were screened
for mature schizonts. The assay was valid only if
>10% of the parasites in the control fully devel-
oped into schizonts with more than three nuclei.
The minimum inhibitory concentration (MIC)
was defined as the lowest drug concentration in
which no such schizonts were observed. Con-
centrations were expressed 106 mol/L of blood.
As recommended by the WHO [1,3], the cut-off
concentrations for in vitro resistance to the
respective drugs was considered as 0.8 106
mol/L of blood for chloroquine and 6.4 106
mol/L of blood for mefloquine. The mean results
for IC50 and IC99 were calculated from all tests
and used as standard assessments for in vitro
sensitivity.
All patients with malaria were admitted to the
Infectious Diseases Hospital for at least 3–5 days.
Clinical follow-up of all patients was carried out
on days 1, 2, 3, 7 and 14 after treatment, with
examination of blood by microscopy on days 3,
5, 7 and 14 and whenever symptoms or fever
were reported. The patients not responding to
chloroquine were mostly detected on the 3rd
day with fever and/or no drop in the parasite
density. The patients who fulfilled the following
criteria were enrolled for in vitro drug sensitivity
testing: pure P. falciparum parasitaemia, 1000
asexual parasites per mL of blood, negative history
of antimalarial drug administration in the 2 weeks
preceding presentation of symptoms, negative
urine test for four aminoquinolines and sulfona-
mides (lignin), and absence of other concomitant
illness.
R E S U L T S A N D D I S C U S S I O N
During the study period a total of 1352 malaria
patients that fulfilled the in vitro drug sensitivity
criteria were enrolled for the study. Of these, 1293
(95.5%) were immigrants from countries where
malaria is endemic, either returning from holidays
in their home countries or coming for the first time
to Kuwait. Fifty-nine (4.5%) patients were Kuwaiti
nationals or resident Europeans with a recent
history of travel to a malaria-endemic country.
The majority of patients were 20–45 years old,
and most of the patients were detected within
1 week of the onset of clinical symptoms. How-
ever, 21 patients were diagnosed after a period of
2 weeks after onset of symptoms. All patients with
malaria were hospitalized for at least 3–5 days and
a standard dose of chloroquine was given to all
patients except those who came from Gujarat
(India) and/or Thailand. The chloroquine,
25 mg/kg was given over 3 days as follows: day
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1, 10 mg/kg followed by 5 mg/kg 6–8 h later; days
2 and 3, 5 mg/kg in a single dose. The patients
from these two areas were given a single 15-mg/
kg dose of mefloquine. It has been reported pre-
viously that>90% of the P. falciparum isolates from
these two areas are resistant to chloroquine [5,11].
Clinical follow-up of all patients was performed
on days 1, 2, 3, 7 and 14 after treatment, with
examination by microscopy of blood on days 3,
5, 7 and 14 and whenever symptoms or fever were
reported. The treatment was changed to quinine or
mefloquine on the third day if fever persisted or
parasitemia did not drop at least 30% of the initial
amount of the parasite density detected on the 1st
day of presentation.
In all, 892 of 1352 (66.0%) P. falciparum isolates
were successfully cultured, and 419 (47%) iso-
lates showed in vitro resistance to choloroquine,
mefloquine, or to both drugs (Table 1). Of the 419
isolates 335 (79.9%) were resistant to chloroquine,
MIC 0.8 106 mol/L of blood, and 141 isolates
(33.7%) were resistant to mefloquine, MIC 6.4
106 mol/L of blood (Table 1). Fifty-six (13.4%)
isolates were resistant to both drugs, and 16
(3.8%) isolates were resistant to mefloquine but
sensitive to chloroquine. The relative drug-resis-
tance pattern of P. falciparum isolates obtained
from patients from different geographical areas
is shown in Table 1: India, Pakistan (39.9%),
Bangladesh (35.9%), Sri Lanka (24.7%) and African
countries (77.2%) (Table 1). The concentration of
chloroquine that inhibited the growth of all para-
sites was 26.4 106 mol/L and 50%, 95% and 99%
effective inhibitory concentrations were 0.385,
2.052 and 5.015 106 mol/L of blood.
Our data showed that chloroquine resistance is
common (>70%) and is widely spread in south-
east Asian and African countries. The relatively
low number of isolates tested for drug resistance in
individuals from African countries was due to
fewer immigrants (<1.0%) from these countries.
The African countries included Uganda, Togo,
Somalia, Nigeria and Liberia. Earlier studies have
documented a high rate of chloroquine resistance
in India, Thailand and Africa [5,11,12] but recent
information on the resistance pattern in Pakistan,
Sri Lanka and Bangladesh is not available for
comparison.
Resistance to mefloquine ranged from 26.2% in
isolates from Sri Lanka to 47.5% in isolates from
African countries; however, resistance to both
chloroquine and mefloquine was relatively un-
common (range 2.4% in Sri Lanka to 29.5% in
Africa) (Table 1). The concentration of mefloquine
that inhibited the growth of all parasites was
71.6 106 mol/L and 50%, 95% and 99% effective
inhibitory concentrations were 0.098 106,
0.885 106 and 1.537 106 mol/L of blood, res-
pectively. The patients not responding to meflo-
quine were given quinine, 500 mg every 8 h for
7–10 days with tetracycline, 500 mg twice daily for
7–10 days. We cannot explain the relatively high
rate of mefloquine resistance in some parts of the
Indian subcontinent and Africa. However, meflo-
quine-resistant strains appear to have been intro-
duced into these areas. The possible clinical
implications of this could be an increase in meflo-
quine treatment failures and the progression of
mild malaria to more severe forms.
As in earlier reports we found more than 70% of
the P. falciparum isolates from India and African
countries to be resistant to chloroquine (Table 1).
However, a relatively high number of P. falciparum
isolates from other malaria endemic countries in
Table 1 Patterns of in vitro drug resistance of 892 Plasmodium falciparum isolates from immigrants and tourists in Kuwait
Drug resistance pattern
Country of
origin or
visited
No. of
isolates
cultured
No. of
resistant
isolates (%)
Chloroquine
n (%)
Mefloquine
n (%)
Chloro. þ Meflo.
n (%)
India 234 172 (73.5) 144 (83.7) 58 (33.7) 30 (17.4)
Pakistan 148 59 (39.9) 45 (72.3) 16 (27.1) 2 (3.4)
Bangladesh 167 60 (35.9) 43 (71.7) 19 (31.7) 2 (3.3)
Sri Lanka 170 42 (24.7) 33 (78.6) 11 (26.2) 1 (2.4)
Africaa 79 61 (77.2) 50 (82.0) 29 (47.5) 18 (29.5)
Othersb 94 25 (26.6) 20 (80.0) 8 (32.0) 3 (12.0)
aAfrican countries included patients/travellers from Uganda, Togo, Somalia, Nigeria and Liberia.
bOther countries included Saudi Arabia, Oman, Thailand and Phillipines.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 734–738
736 Clinical Microbiology and Infection, Volume 8 Number 11, November 2002
south-east Asia were still sensitive to chloroquine:
Pakistan (>60%), Bangladesh (>65%) and Sri Lanka
(>75%) (Table 1). Earlier studies have shown a
high frequency of chloroquine resistance in many
countries of south-east Asia, South America and
across sub-Saharan Africa [5,13–17]. In addition,
different foci of endemic malaria within the coun-
try also show marked variation of the prevalence
of drug-resistant P. falciparum isolates [11,12].
In Gujarat (India) more than 85% P. falciparum
isolates show chloroquine resistance whereas the
prevalence is markedly lower (10–37%) in other
parts of India [11].
Imported malaria remains a great health pro-
blem in Kuwait. Each year more than 800 cases are
detected in Kuwait among the >500 000 immi-
grants who enter Kuwait to reside or to work.
Such individuals form the bulk (45%) of the total
expatriate population in Kuwait. Although Egyp-
tians form the biggest single immigrant group
(approx. 20%) in Kuwait, less than 0.5% of all
malaria cases were seen among Egyptians and
no drug-resistant isolate was detected within this
population. The immigrants from India form the
second biggest group (19%) followed by Bangla-
desh and Sri Lanka (10% each) and, Pakistan (8%).
A large number of immigrants from these coun-
tries spend their holidays in their respective home
countries and are at risk of malaria infection. The
patients with malaria infection present with symp-
toms at various intervals after their arrival in
Kuwait, those with asymptomatic malaria being
detected as slide-positive cases during their health
check-up on first arrival. In addition, Kuwaiti na-
tionals and other resident Europeans travelling to
malaria-endemic countries are exposed to malaria
infection and present with symptoms in Kuwait.
In conclusion, this study highlights the impor-
tant trend of drug resistance in P. falciparum
malaria parasites in the immigrant population
from south-east Asian and African countries. A
significant change in the drug sensitivity pattern of
P. falciparum isolates from these countries will
have an important impact on the future therapeu-
tic, as well as prophylactic, policies for P. falci-
parum infection in Kuwait.
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